⌕
Intellia Therapeutics · NTLA · Nasdaq
Tenet 41 · Weak
Compare
$9.78−0.81%At closeTenet 41 · Weak
$9.78−0.08 (−0.81%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Intellia Therapeutics (NTLA) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice

20 figures withheld by our checks. Each blank figure names its reason.

Business engineGrowing fast: revenue compounds ~19.6%/yr (FY21→FY25), net margin −609.9%. Worth your attention in FY25: Share count (+52.9%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲16.9%
67.7
FY21→FY25CAGR +19.6%/yr
Net income ($M)▲20.5%
−412.7
FY21→FY25CAGR —
Free cash flow ($M)▼11.6%
−395.9
FY21→FY25CAGR —
Diluted EPS▲27.4%
−3.81
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+52.9%

70.9mn → 108.4mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

Capex
$1.1M

−80.5% YoY in FY25 · 1.7% of revenue.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)67.7Revenue0.0COGS−388.9R&D−119.8SG&A−441.0Op income28.3Tax & other−412.7Net income

-610¢ of every revenue dollar becomes profit.

Margin trend · direction beats level Operating Net
108530%sector median net margin ~3%FY21FY25

Net margin -609.9% is below the sector median. This filer reports no gross profit line, so that margin is not drawn.

The receipt · income statement · FY21–FY25 USD millions except per-share & ratios · hover a line for its definition
The annual and quarterly statements are struck on share counts that differ by a factor of 0.7731, so per-share figures cannot be compared across the two tables. Each table's per-share figures are on its own share basis.
USD millions except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
52.967.757.936.352.133.1▲16.9%+19.6%
Cost of revenue
—0.00.00.00.00.0——
Gross profit
—A—A—A—A—A—A——
Research & development
335.3388.9466.3435.1420.0229.8▼16.6%+14.1%
Selling, general & admin
151.9119.8125.8116.590.371.1▼4.8%+13.9%
Total operating expenses
487.2508.7592.1551.7510.3300.9▼14.1%+14.0%
Operating incomefeeds ROC rank
−434.3−441.0−534.3−515.3−458.2−267.9▲17.5%—
Other income, net
7.428.716.037.8−16.0−2.2——
Pretax income
−426.9−412.3−518.3−477.5−474.2−270.1▲20.5%—
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−426.1−412.7−519.0−481.2−474.2−267.9▲20.5%—
Per share
Diluted EPSbuyback-sensitive
−3.33−3.81−5.25−5.42−6.16−3.78▲27.4%—
Diluted shares (mn)
140.19108.3898.8588.7776.9770.89▲9.6%+11.2%
Margins
Gross margin
—A—A—A—A—A—A——
Operating margin
−821.2%−651.7%−923.1%−1420.5%−879.0%−810.4%▲271.4pp+158.7pp
Net margin3rd pct in Healthcare
−805.7%−609.9%−896.8%−1326.5%−909.8%−810.5%▲286.9pp+200.6pp
† TTM = trailing four quarters through 2026-09-30.A Withheld: cost of revenue is not on file, so the gross margin is not measured.
FY15 – FY20 · 6 more years
Unlock the full history →
5 more years of statements and CSV export are on Premium, and 6 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-26 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Intellia Therapeutics' revenue last fiscal year?

Intellia Therapeutics reported revenue of $67.7M in fiscal 2025, up 16.9% from fiscal 2024.

What was Intellia Therapeutics' net income?

Intellia Therapeutics reported net income of −$412.7M in fiscal 2025, a net margin of −609.9%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.